Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 6Terminated 2Withdrawn 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 3Lymphoid 1Breast 1

Conditions

Pancreatic Neoplasms 1Lymphoma, T-Cell 1Lymphoma, B-Cell 1Lymphoma 1

Interventions

Rituximab 55Cyclophosphamide 45Vincristine 23fludarabine phosphate 21Cytarabine 20fludarabine 19Etoposide 19Prednisone 18Bendamustine Hydrochloride 18ibrutinib 17Methotrexate 17Doxorubicin 17Lenalidomide 15Radiotherapy 14Peripheral Blood Stem Cell Transplantation 13Filgrastim 12venetoclax 11Melphalan 11Dexamethasone 11Whole-Body Irradiation 8Tacrolimus 8Busulfan 8Brentuximab Vedotin 8Biopsy 8pembrolizumab 7duvelisib 7Nivolumab 7Mycophenolic Acid 7Gemcitabine 7Cyclosporine 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × entinostat × Lymphoid × Clear all
NCT03925428 2020-09-28

Testing a New Anti-cancer Drug Combination, Entinostat and GSK525762C, for Advanced and Refractory Solid Tumors and Lymphomas

National Cancer Institute (NCI)

Phase 1 Withdrawn
GastrointestinalLymphoid

Lymphoma, Pancreatic Neoplasms, Lymphoma, B-Cell, Lymphoma, T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡